ABVC BioPharma

ABVC · Nasdaq · United States

Share price · ABVC

$0.91+0.04 (+5.11%) 3M

close as of 2026-11-18 · 24h delayed · vol 104K (2.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ABVC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 15 Oct 2026-8.6%
  2. 3 Sep 2026+15.7%

    Nothing announced by ABVC that day or the session before.

  3. 9 Jul 2026-28.2%

    Nothing announced by ABVC that day or the session before.

  4. 1 Jul 2026+12.0%

    Nothing announced by ABVC that day or the session before.

  5. 26 May 2026+13.2%

    Nothing announced by ABVC that day or the session before.

  6. 6 Apr 2026+27.5%

    Nothing announced by ABVC that day or the session before.

  7. 1 Apr 2026+11.3%

    Nothing announced by ABVC that day or the session before.

  8. 2 Mar 2026+13.0%

    Nothing announced by ABVC that day or the session before.

  9. 23 Feb 2026-7.3%
  10. 5 Feb 2026-15.8%

    Nothing announced by ABVC that day or the session before.

Share of unusual movement by asset

For each asset, the share of ABVC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—10%
Sessions with no dated event—90%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
Polygalae radix extract (active components: tenuifolin, polygalasaponins, etc.)Botanical
Major Depressive DisorderAttention Deficit Hyperactivity Disorder

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
February 2028 (1)
PDC-1421Phase 1/2Major Depressive Disorder
Est. primary completion 2028-02-28 · NCT03833206 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—<$0.1M<$0.1M+ $0.1M short-term inv.—-$0.4M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—<$0.1M<$0.1M+ $0.1M short-term inv.$0.7M-$0.2M operating cash flowreport ↗
2026-Q1—<$0.1M$0.1M+ $0.1M short-term inv.$1.6M-$0.9M operating cash flowreport ↗
2025-Q3$0.8M<$0.1M$0.8M+ $0.1M short-term inv.$1.3M-$0.1M operating cash flowreport ↗
2025-Q2—<$0.1M$1.1M+ $0.1M short-term inv.$2.3M-$0.9M operating cash flowreport ↗
2025-Q1—<$0.1M$0.8M+ $0.1M short-term inv.$0.8M-$0.5M operating cash flowreport ↗
2024-Q3$0.4M<$0.1M$0.8M+ $0.1M short-term inv.$0.2M$0.2M operating cash flowreport ↗
2024-Q2$0.1M<$0.1M$0.7M+ $0.1M short-term inv.$0.9M-$1.0M operating cash flowreport ↗
2024-Q1$0$0.1M$0.7M+ $0.1M short-term inv.$3.9M-$0.5M operating cash flowreport ↗
2023-Q3<$0.1M$0.1M$1.1M+ $0.1M short-term inv.$3.3M-$1.4M operating cash flowreport ↗
2023-Q2<$0.1M$0.5M$0.7M+ $0.1M short-term inv.$2.3M-$0.9M operating cash flowreport ↗
2023-Q1$0.1M$0.3M$1.8M+ $0.1M short-term inv.$1.8M-$1.5M operating cash flowreport ↗
2022-Q3<$0.1M$0.3M$2.0M+ $0.1M short-term inv.$3.7M-$0.5M operating cash flowreport ↗
2022-Q2$0.3M$0.5M$3.6M+ $0.1M short-term inv.$1.9M-$3.4M operating cash flowreport ↗
2022-Q1<$0.1M$0.4M$3.4M+ $0.1M short-term inv.$6.1M-$3.0M operating cash flowreport ↗
2021-Q3$0.1M$0.3M$4.5M+ $0.1M short-term inv.$1.9M-$2.7M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$0.1M$1.3M+ $0.1M short-term inv.$2.0M-$3.0M operating cash flowreport ↗

ABVC BioPharma did not disclose revenue for fiscal 2025, compared with $0.51M in the prior year. R&D spend was $0.12M, down 33.3% YoY, while cash and equivalents stood at $1.33M. The company reported a net loss of $7.91M and a quarterly net burn of $7.91M.

Management highlighted a 179% YoY increase in total assets to $21.06M, largely driven by a rise in net property and equipment to $12.84M and strategic land acquisitions in Taiwan, including properties valued at $4.6M and approximately $8.0M. Core programs remain licensed to subsidiaries and related parties (CNS to AiBtl BioPharma, oncology to OncoX BioPharma, and ophthalmology to ForSeeCon Eye Corporation), a structure meant to reduce direct clinical cash burn while retaining licensing economics and equity participation. The pipeline includes six drugs and one medical device, ABV-1701/Vitargus, and the release did not provide financial guidance.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.5M$0.2M$0.9M+ $0.1M short-term inv.$1.2M-$1.8M operating cash flowreport ↗
2023-FY$0.1M$1.1M$0.7M+ $0.1M short-term inv.$2.6M-$4.2M operating cash flowreport ↗
2022-FY$1.0M$2.7M$1.4M+ $0.1M short-term inv.$4.1M-$7.4M operating cash flowreport ↗
2021-FY$0.4M$1.0M$6.6M+ $0.1M short-term inv.$3.0M-$7.6M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2012-01-27Stolz Kevin Patrick · VP & ControllerAward / grant6,250——Form 4
2011-05-25Krotine Frank Thomas · COOAward / grant (derivative)300,000$0.20$60KForm 4
2011-05-11Ramsey Sally Judith · director, VP New Product DevelopmentAward / grant (derivative)2,100,000$0.20$420KForm 4
2011-05-11Crockett Robert G · Chief Executive OfficerAward / grant (derivative)1,800,000$0.20$360KForm 4
2011-05-11IANNOTTI DANIEL V · VP, General Counsel & SecretarAward / grant (derivative)300,000$0.20$60KForm 4
2011-05-11Stolz Kevin Patrick · CFO & ControllerAward / grant (derivative)50,000$0.20$10KForm 4
2010-08-12Juliano James · director, 10% ownerAward / grant (derivative)100,000$0.10$10KForm 4
2010-05-11Nirta Joseph · directorOpen-market purchase10,000$0.15$2KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 13 reporting institutions held 0.8M shares ($792K, 3.1% of shares outstanding).

#InstitutionSharesValue
1GEODE CAPITAL MANAGEMENT, LLC221,169$215K
2VANGUARD CAPITAL MANAGEMENT LLC190,574$185K
3VANGUARD FIDUCIARY TRUST CO97,363$94K
4RENAISSANCE TECHNOLOGIES LLC95,100$92K
5STATE STREET CORP72,800$71K
6BlackRock, Inc.56,442$55K
7NORTHERN TRUST CORP32,087$31K
8TWO SIGMA SECURITIES, LLC21,023$20K
9DIMENSIONAL FUND ADVISORS LP12,227$12K
10Squarepoint Ops LLC10,547$10K
11Tower Research Capital LLC (TRC)5,423$5K
12UBS Group AG1,771$2K
13ROYAL BANK OF CANADA17$0